Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

599

Shown on this page

Current sort

Live official records

Conditions: Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
Interventions: GEM/DOX + TGFBi expanded NK cells; Biological
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 2 Years to 40 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: South Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more

Conditions: Community Acquired Pneumonia (CAP), Community Acquired Pneumonia
Interventions: Immediate Antibiotic Prescribing Group Instructions, Safety Net Antibiotic Prescribing (SNAP) Group Instructions; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Months to 71 Months
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Atlanta, Georgia • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more

Conditions: Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions: Elimusertib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 30 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Propionic Acidemia
Interventions: mRNA-3927; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: Not listed
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Stanford, California • Miami, Florida + 11 more

Conditions: Type 1 Diabetes
Interventions: iHERO Toolkit Resource; Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Cleveland, Ohio + 1 more

Conditions: Alexander Disease
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: GLP-1, GIP; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 150,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 50 more

Conditions: Recurrent Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 5 Years to 50 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 84
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Enasidenib, Enasidenib Mesylate; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 24 Months to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 23 more

Conditions: Congenital Hyperinsulinism
Interventions: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC; Drug
Lead sponsor: Rezolute; Other
Eligibility: 3 Months to 45 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Li-Fraumeni Syndrome
Interventions: Whole Body MRI; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania

About this Children's Hospital of Philadelphia institution page

What this page lists: ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Children's Hospital of Philadelphia

Filter and sort this campus

Live official records

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes

Evaluation of Outcome Metrics in Alexander Disease

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

RZ358 Treatment for Congenital Hyperinsulinism

Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes

About this Children's Hospital of Philadelphia institution page